PSMA PET/CT显像对前列腺癌放射治疗的影响
本文综述了前列腺特异性膜抗原(PSMA)靶向PET显像在前列腺癌放射治疗中的应用。PSMA PET可识别适合外照射放疗的残留或复发病灶,显著提高复发灶检测的敏感性和特异性,即使在极低PSA水平下亦然,从而可能实现更个体化的放疗计划并减少邻近正常组织受照。但PSMA PET对患者长期结局的影响尚待确定。
要点
- PSMA PET可识别适合外照射放疗的残留或复发病灶,并用于放疗计划中靶区勾画。
- PSMA PET整合入常规评估后,对复发灶的敏感性和特异性显著提高,即使PSA值极低时亦然。
- PSMA PET可能改变更早期应用放疗的行为,但其对患者结局的长期影响尚待确定。
核心结论
- PSMA PET显像整合入前列腺癌常规评估显著提高了复发灶检测的敏感性和特异性,即使在极低PSA值下亦然,可能实现更个体化的放疗计划并有助于减少邻近正常组织受照。
- PSMA PET的引入可能改变更早期应用放疗的行为,但其对患者结局的长期影响尚待确定。
研究设计与样本
- 本文为综述,旨在概述PSMA-PET/CT显像在前列腺癌放射治疗中的应用。
主要发现
- PSMA PET的一个直接影响是识别适合外照射放疗的残留或复发病灶。
- 根治性前列腺切除术后生化失败时,挽救性放疗是潜在的治愈选择,寡转移性前列腺癌的转移灶导向放疗目前正在研究中。
- 为最大化治愈机会,照射肿瘤体积应完全覆盖实际病变范围,因此准确估计病变靶区位置和勾画对放疗计划至关重要。
- PSMA PET显像整合入前列腺癌常规评估显著提高了复发灶检测的敏感性和特异性,即使在极低PSA值下亦然。
临床怎么用
- 原文未据此给出推荐。
局限性
- PSMA PET对患者结局的长期影响尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging of prostate cancer is rapidly evolving with the introduction of the novel prostate-specific membrane antigen (PSMA)-targeted PET imaging tool for managing recurrent prostate cancer. One immediate impact of PSMA PET is the identification of residual or recurrent lesions that are amenable to external beam radiotherapy. Radiotherapy is used as a definitive curative treatment option for patients with localized prostate cancer alone or in combination therapy. In the setting of biochemical failure after radical prostatectomy, salvage radiation is a potential curative option, and the application of metastasis-directed radiotherapy in the setting of oligometastatic prostate cancer is currently being studied. To maximize the chances of curative therapy, the irradiated tumor volumes should completely encompass the actual extent of disease. Thus, an accurate estimation of the location and delineation of disease targets is critical for radiotherapy planning. The integration of PSMA PET imaging into the routine evaluation of prostate cancer has markedly improved sensitivity and specificity for recurrent disease, even at very low PSA values, which may enable further tailored radiation treatment plans, and help reduce the risk of radiation to adjacent normal tissues. However, while the introduction of PSMA PET will likely change behavior regarding earlier application of radiotherapy, the long-term impact of PSMA PET on patient outcomes is yet to be determined. The aim of the review is to give an overview of the use of PSMA-PET/CT imaging in the setting of radiation therapy for prostate cancer.
引用
- Mena E, Lindenberg L, Choyke P, et al. The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment. Semin Nucl Med. 2022. PMID: 35016755. doi:10.1053/j.semnuclmed.2021.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。